A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03762850|
Recruitment Status : Recruiting
First Posted : December 4, 2018
Last Update Posted : January 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Immunoglobulin A Nephropathy||Drug: sparsentan Drug: irbesartan||Phase 3|
This is a randomized, multicenter, double-blind, parallel-group, active-control study. Approximately 280 patients aged ≥18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan.
The purpose of the study is to evaluate the potential benefit of sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment.
Patients enrolled in the PROTECT study (Protocol 021IGAN17001) will be those at high risk of progressing to renal failure. They will be randomly assigned n a 1:1 ratio to either sparsentan or irbesartan, as the active control (current standard treatment) at the Day 1 (Randomization) visit. Study medication (sparsentan and irbesartan) will be administered as a single oral morning dose.
The primary analysis is change in proteinuria (urine protein/creatinine ratio) from baseline at Week 36 in sparsentan-treated patients as compared to irbesartan-treated patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||280 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy|
|Actual Study Start Date :||December 20, 2018|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||April 2023|
Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg and continue treatment to Week 110.
Target dose of 400 mg daily
Other Name: RE-021
Active Comparator: irbesartan
Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
Target dose of 300 mg daily
Other Name: Irbesartan Tablets USP
- Urine protein/creatinine ratio (UP/C) at Week 36 [ Time Frame: After the last patient randomized has undergone the Week 36 visit ]The primary efficacy endpoint is the change from baseline in the urine protein/creatinine ratio (UP/C), based on a 24-hour urine sample, at Week 36.
- Overall eGFR change from baseline [ Time Frame: Week 114 post-randomization ]Change in eGFR from baseline (Week 0) to 4 weeks post-cessation of randomized treatment (Week 114).
- eGFR over a 52-week period [ Time Frame: Week 58 post-randomization ]The rate of change in estimated glomerular filtration rate (eGFR) over a 52-week period following the initial acute effect of randomized therapy (the initial acute effect of randomized therapy is defined as the first 6 weeks of randomized treatment with study medication; thus, the analysis is from 6 weeks post-randomization to 58 weeks post-randomization).
- eGFR over a 104-week period [ Time Frame: Week 110 post-randomization ]The rate of change in estimated glomerular filtration rate (eGFR) over a 104-week period following initial acute effect of randomized therapy (the initial acute effect of randomized therapy is defined as the first 6 weeks of randomized treatment with study medication; thus, the analysis is from 6 weeks post-randomization to 110 weeks post-randomization).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03762850
|Contact: Retrophin Call Centeremail@example.com|
|Contact: Michelle Greenmanfirstname.lastname@example.org|
|United States, Alabama|
|Nephrology Associates, P.C.||Recruiting|
|Homewood, Alabama, United States, 35209|
|Principal Investigator: Phillip N Madonia, MD|
|United States, California|
|California Medical Research Associates, Inc.||Recruiting|
|Northridge, California, United States, 91324|
|Principal Investigator: Ramachandra V Patak, MD|
|California Research Foundation||Recruiting|
|San Diego, California, United States, 92123-1881|
|Principal Investigator: Donald M Brandon, MD|
|United States, Colorado|
|Colorado Kidney Care||Recruiting|
|Denver, Colorado, United States, 80218|
|Principal Investigator: Bradley A Marder, MD|
|United States, Texas|
|Texas Research Institute||Recruiting|
|Fort Worth, Texas, United States, 76104|
|Principal Investigator: Saravanan Balamuthusamy, MD|
|Australia, New South Wales|
|Prince of Wales Hospital||Recruiting|
|Randwick, New South Wales, Australia, 2031|
|Principal Investigator: Zoltan H Endre, MD|
|West Tallinn Central Hospital||Recruiting|
|Tallinn, Estonia, 10617|
|Principal Investigator: Madis Ilmoja, MD|
|North Estonia Medical Centre Foundation||Recruiting|
|Tallinn, Estonia, 13419|
|Principal Investigator: Kadri Lilienthal, MD|
|Tartu University Hospital||Recruiting|
|Tartu, Estonia, 50406|
|Principal Investigator: Mai Rosenberg, MD|
|Hospital of Lithuanian University of Health Sciences Kauno Klinikos||Recruiting|
|Kaunas, Lithuania, LT-50161|
|Principal Investigator: Inga Arune Bumblyte, MD, PhD|
|Study Director:||Radko Komers, MD, PhD||Retrophin, Inc.|